| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer A de Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, ... Journal of Clinical Oncology 18 (16), 2938-2947, 2000 | 5090 | 2000 |
| ESMO consensus guidelines for the management of patients with metastatic colorectal cancer E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ... Annals of Oncology 27 (8), 1386-1422, 2016 | 3468 | 2016 |
| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2571 | 2011 |
| Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, ... Annals of oncology 30 (8), 1194-1220, 2019 | 2419 | 2019 |
| ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ... Annals of oncology 23 (10), 2479-2516, 2012 | 1863 | 2012 |
| Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up R Glynne-Jones, L Wyrwicz, E Tiret, G Brown, C Rödel, A Cervantes, ... Annals of Oncology 28, iv22-iv40, 2017 | 1805 | 2017 |
| Capecitabine as adjuvant treatment for stage III colon cancer C Twelves, A Wong, MP Nowacki, M Abt, H Burris III, A Carrato, J Cassidy, ... New England Journal of Medicine 352 (26), 2696-2704, 2005 | 1695 | 2005 |
| Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up EC Smyth, M Verheij, W Allum, D Cunningham, A Cervantes, D Arnold Annals of oncology 27, v38-v49, 2016 | 1692 | 2016 |
| Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up E Van Cutsem, A Cervantes, B Nordlinger, D Arnold Annals of oncology 25, iii1-iii9, 2014 | 1387 | 2014 |
| Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up R Labianca, B Nordlinger, GD Beretta, S Mosconi, M Mandalà, ... Annals of oncology 24, vi64-vi72, 2013 | 1103 | 2013 |
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ... Journal of clinical oncology 24 (3), 394-400, 2006 | 1081 | 2006 |
| Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in … RR Bahadoer, EA Dijkstra, B van Etten, CAM Marijnen, H Putter, ... The Lancet Oncology 22 (1), 29-42, 2021 | 1045 | 2021 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 910 | 2015 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of Oncology 29, iv238-iv255, 2018 | 894 | 2018 |
| Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six … D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ... Annals of oncology 28 (8), 1713-1729, 2017 | 886 | 2017 |
| First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement J Tabernero, GI Shapiro, PM LoRusso, A Cervantes, GK Schwartz, ... Cancer discovery 3 (4), 406-417, 2013 | 775 | 2013 |
| Integration of oncology and palliative care: a Lancet Oncology Commission S Kaasa, JH Loge, M Aapro, T Albreht, R Anderson, E Bruera, C Brunelli, ... The lancet oncology 19 (11), e588-e653, 2018 | 683 | 2018 |
| Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Glimelius, E Tiret, A Cervantes, D Arnold Annals of oncology 24, vi81-vi88, 2013 | 662 | 2013 |
| Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) GJS Rustin, I Vergote, E Eisenhauer, E Pujade-Lauraine, M Quinn, ... International Journal of Gynecologic Cancer 21 (2), 2011 | 632 | 2011 |
| Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E Van Cutsem, B Nordlinger, A Cervantes Annals of oncology 21, v93-v97, 2010 | 605 | 2010 |
Susana RosellóMedical Doctor in Hospital Clinico Universitario of Valencia, Spain在 incliva.es 的电子邮件经过验证
